405 related articles for article (PubMed ID: 30152052)
1. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
[TBL] [Abstract][Full Text] [Related]
9. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
11. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
An J; Lv W
Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
[TBL] [Abstract][Full Text] [Related]
12. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
[TBL] [Abstract][Full Text] [Related]
16. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
19. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
Chen L; Zhu X; Li D; Cai X
J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial.
Park CK; Oh IJ; Kim KS; Choi YD; Jang TW; Kim YS; Lee KH; Shin KC; Jung CY; Yang SH; Ryu JS; Jang SH; Yoo SS; Yong SJ; Lee KY; In KH; Lee MK; Kim YC
Clin Lung Cancer; 2017 Jul; 18(4):e289-e296. PubMed ID: 28185792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]